Cosmos Health, a healthcare and pharmaceutical company traded on Nasdaq under the ticker COSM, has entered the animal health market with the launch of its C-Scrub brand, an antiseptic skin cleanser the company is positioning for veterinary applications.

The announcement marks the company's first move into animal health, extending a product line it already offers in the human health space. C-Scrub is a chlorhexidine-based antiseptic skin cleanser, according to the company's announcement, and the animal health version will target use in veterinary settings where antiseptic skin preparation is routine — pre-surgical sites, catheter placement, and general wound care.

Chlorhexidine gluconate remains one of the most widely used antiseptic agents in both human and veterinary medicine for skin antisepsis, and the C-Scrub launch places Cosmos Health in a category that includes established veterinary antiseptic products from larger animal health manufacturers.

The company has not yet detailed the specific formulations, concentrations, or product sizes it will offer in the animal health channel, nor has it named distribution partners or launch markets. No pricing information was included in the announcement.

Cosmos Health has also not disclosed whether the veterinary C-Scrub products have received regulatory approval from the U.S. Food and Drug Administration's Center for Veterinary Medicine (FDA CVM) or whether the company plans to market the products under existing over-the-counter antiseptic categories. Antiseptic products for veterinary use in the United States may fall under different regulatory pathways depending on claims and formulation.

The launch comes as the animal health sector continues to attract interest from human pharmaceutical companies seeking growth outside their core markets. The global animal health market has expanded steadily over the past decade, driven by rising pet ownership, increased spending on companion-animal care, and growing demand for livestock health products.

For veterinary practices, the entry of a new supplier in the antiseptic category could add competition in a product segment where practices routinely purchase skin preparation products for surgical and procedural use. Practice managers evaluating new suppliers typically weigh formulation consistency, regulatory status, and pricing against established brands.

Cosmos Health operates a diversified healthcare business that includes pharmaceutical wholesale distribution, a pharmacy, and proprietary branded and generic medicines, according to the company. The C-Scrub brand is among its proprietary offerings, and the animal health launch represents an extension of that brand into a new market segment.

The company stated that the animal health market entry is part of its broader strategy to expand its proprietary product portfolio. It did not provide revenue projections or sales targets for the veterinary launch.

Whether C-Scrub gains traction with veterinarians will depend on factors including regulatory clearance, distribution reach, and how the product's formulation and pricing compare with antiseptic products already established in clinics and hospitals. Further details on availability, regulatory status, and product specifications are expected as the company rolls out the brand.